Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring
Tyrosine kinase inhibitors (TKIs) have emerged as the first-line small molecule drugs in many cancer therapies, exerting their effects by impeding aberrant cell growth and proliferation through the modulation of tyrosine kinase-mediated signaling pathways. However, there exists a substantial inter-i...
Saved in:
Main Authors: | Lan Chen (Author), Yuan Zhang (Author), Yi-Xin Zhang (Author), Wei-Lai Wang (Author), De-Mei Sun (Author), Peng-Yun Li (Author), Xue-Song Feng (Author), Yue Tan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Benzodiazepines in complex biological matrices: Recent updates on pretreatment and detection methods
by: Yi-Xin Zhang, et al.
Published: (2023) -
Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
by: Xin Li, et al.
Published: (2024) -
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
by: Xiaohong Liu, et al.
Published: (2024) -
A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
by: Xue Han, et al.
Published: (2023) -
Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022)